The Latest Articles from The Life Sciences Report

Telemedicine Co. Surges on Revenue News

  ()
As internet-enabled health care becomes more accepted in the wake of the pandemic, telemedicine company Reliq Health Technologies Inc. is seeing its revenue soar.

Biopharma Gains Two Cancer Cell Therapy Programs and a Target Price 10 Times Current

Research Report
  ()
This developer of cancer immunotherapies will take possession of these clinical-stage assets in a transaction with GSK and subsequently advance them toward approval, noted a ROTH Capital Partners report.

Potential ROI With German Biopharma Co. Notable

Research Report
  ()
This firm, with eight treatment candidates for mental health disorders in development, boasts a catalyst-rich next two months, noted a ROTH Capital Partners report.

Expert Says Buy Pharma Co. Stock 'as Soon as Possible'

Contributed Opinion
  ()
Algernon Pharmaceuticals has entered into a clinical trial agreement with Yale and caught expert Clive Maund's attention. In light of this, Maund reviews the company's chart to tell you when he believes you should buy it.

Biopharma Co. Shows Large Potential Return

Research Report
  ()
Palatin Technologies Inc.'s third-party clinical trial of Vyleesi in women with hypoactive sexual desire disorder was just published in the Journal of Clinical Investigation, and the biopharma offers investors significant potential return, noted an H.C. Wainwright & Co. report.

Companies Use Blockchain To Connect Hemp Growers, Consumers

  ()
Industrial hemp is legal in all 50 states, and companies are working to get CBD, insulation, textiles, and biofuel made from it to the masses. These three companies hope their partnership will help connect the growers and buyers.

Biotech Co.'s Target Price Over Three Times Current

Research Report
  ()
Expanded interim data from the Phase 2 trial of this biotech's lead asset PDS0101 in HPV16-associated cancers are consistent with previously reported results from the same study. Read more to discover why H.C Wainright & Co. believes this stock is a Buy with a target price over three times the current.

Biopharma Co. Partners With Merck for Combo Drug Trial

Research Report
  ()
With this and other clinical studies, the U.S. company has a busy and, thus, catalyst-rich Q4/22 ahead, noted an H.C. Wainwright & Co. report.

Chen Reveals His Picks for Last Quarter

  ()
Asset manager Chen Lin's picks for the home stretch of 2022 include several biotechs and some precious metals companies.

Biopharma Target Price 10 Times Current

Research Report
  ()
Read to learn why ROTH Capital Partners gave Atai Life Sciences NV a Buy rating and a target price 10 times its current.
Tags:  Psychedelics

Biotech Co.'s Drug Showing 'Early Signs of Benefit'

Research Report
  ()
With this upcoming analysis, the board will determine whether the Phase 2b/3 trial may continue to completion, noted a ROTH Capital Partners report.

Trial Results of New Drug for An Eye Disease 'Encouraging'

Research Report
  ()
The data suggest this treatment could be safer and more effective in treating proliferative vitreoretinopathy than compounded methotrexate, noted a Laidlaw & Co. report.

Co. Uses RNA Editing as Treatment for Rare Disease

Research Report
  ()
The firm plans to advance its alpha-1 antitrypsin deficiency program into the clinic next year, noted an H.C. Wainwright & Co. report.

Interim Results From Phase 2b Trial Are 'Encouraging'

Research Report
  ()
Data show the biotech's compound had a positive effect on several noninvasive measures, noted a ROTH Capital Partners report.

Showing Results: 26 to 50 of 181 Prev Next